Current Clinical Trials

Description:  Advanced Solid Tumors:   ABBV-400 as Monotherapy-A Global First-in-Human Study

Target Patient Population: All solid tumors

Study Design: Study drug is administered IV every 3 weeks

For more information on this trial, read its profile on clinicaltrials.gov here.

C-1400-01 (AGEN1777) (Agenus, Inc.)

Description:  A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination with PD-1 Inhibition in Patients With Advanced Solid Tumors

Target Population:  All solid tumors.  To be given as single agent or in combination with Balstilimab

Study Design:  Study drug is administered IV every 3 weeks.

Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

ALPN-202 – NEON-1 (Alpine Immune Sciences)

Description:  An open-Label Study of ALPN-202 In Subjects With Advanced Malignancies (NEON-1)

Target Patient Population: Currently in expansion for Melanoma, Renal cell  and PDL1 positive cancers only

Study Design: Study drug is administered IV every 1 or 3 weeks

ALPN-202 – NEON-2 (Alpine Immune Sciences)

 Description:  An open-Label Study of ALPN-202 Combined With PD-1 Inhibition In Subjects With Advanced Malignancies (NEON-2)

Target Patient Population:.  All solid tumors

Study Design: Study drug is administered IV every 1 or 3 weeks

BBI-20201001 (Bolt)

Description:   Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2-Expressing Solid Tumors

Target Patient Population: Advanced solid tumor patients with IHC 2+/3+/or Her2 amp on NGS/FISH/CISH. 

Study Design:  Study Drug will be administered IV every 3 weeks. 

A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor (SERENA-6)

Principal Investigator: Dr. Amy VanderWoude

For more information on this trial, read its profile on clinicaltrials.gov here.

Description:  A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors

Target Patient Population:  Ovarian, Primary peritoneal or Fallopian, Breast (HER2-, HR+), Triple Negative Breast, Endometrial, Squamous Non Small Cell Lung, Cholangiocarcinoma, Gallbladder cancers.

Study Design:  Drug is administered IV 21 day cycle (Day 1, 8 or Day 1 only)

Description:  A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients with Advanced Solid Tumors and Expansion in Patients with Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer and Pancreatic Cancer

Target Patient Population:  Currently in Dose Escalation with all Solid Tumors. 

Study Design:  Drug is administered IV every 3 weeks.

A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency (CAPItello-281)

Principal Investigator: Dr. Eric Batts

For more information on this trial, read its profile on clinicaltrials.gov here.

• • A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumours
  • PI: Dr. Chandana
  • Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion

For more information on this trial, read its profile on clinicaltrials.gov

Description:   A Phase I-II, First –in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies  

Target Patient Population: .  Currently only open for gastric cancer. 

Study Design:   Drug is given IV every 2 weeks

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Principal Investigator: Dr. Sreenivasa Chandana

For more information on this trial, read its profile on clinicaltrials.gov here.

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Principal Investigator: Dr. Sreenivasa Chandana

For more information on this trial, read its profile on clinicaltrials.gov here.

Description: A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination with Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies

Target Patient Population:  NSCLC (Adeno), Pancreatic, Cholangiocarcinoma, Metastatic Colorectal, Gastric, Esophageal, Mesothelioma and Squamous cell Head & Neck

Study Design:  Both Drugs are given IV every 2 weeks of a 28 day cycle

• • A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC-9)
  • PI: Dr. Chen
  • Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion

• GENMAB (GCT1046-04)
  • A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor
  • PI: Dr. Chen
  • Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion

• • A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer
  • PI: Dr. Chen
  • Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion

• • A Randomized, Double-Blind, Phase 3 Study of MK-7684A Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer
  • PI: Dr Chen
  • Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion

Description:  A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Cancers

Target Patient Population:   Melanoma, Ovarian, Non Small Cell Lung Cancer, Colorectal and Pancreatic cancers

Study Design:  Drug is given IV weekly.

Description:  A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors

Target Patient Population:  Ovarian, Primary peritoneal or Fallopian, Breast (HER2-, HR+), Triple Negative Breast, Endometrial, Squamous Non Small Cell Lung, Cholangiocarcinoma, Gallbladder cancers.

Study Design:  Drug is administered IV 21 day cycle (Day 1, 8 or Day 1 only)

Description: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma

Principal Investigator: Dr. Brett Brinker

For more information on this trial, read its profile on clinicaltrials.gov here.

• • • PHASE III RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY
    • PI: Dr. Brinker

• • A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
  • PI: Dr. Brinker
  • Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Primary Investigator: Dr. Erin Pettijohn

For more information on this trial, read its profile on clinicaltrials.gov here.

• • A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS
  • PI: Dr. Brinker

• • Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion

AT148002 (ALX Oncology)

 Description:   A Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS)

Mechanism of Action:  ALX148 is a CD47 blocker.

Target Patient Population: High Risk MDS

Study Design:  Study Drug will be administered IV every 2 or 4 weeks.  Combination drug, Azacitidine given as would Standard of Care.

ALPN-202 – NEON-1 (Alpine Immune Sciences)

Description:  An open-Label Study of ALPN-202 In Subjects With Advanced Malignancies (NEON-1)

Target Patient Population: Currently in expansion for Melanoma, Renal cell  and PDL1 positive cancers only

Study Design: Study drug is administered IV every 1 or 3 weeks

A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency (CAPItello-281)

Principal Investigator: Dr. Eric Batts

For more information on this trial, read its profile on clinicaltrials.gov here.

• • A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumours
  • PI: Dr. Chandana
  • Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion

For more information on this trial, read its profile on clinicaltrials.gov

CPI-0209-01 (Constellation)

Description:   A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors

Target Patient Population:  In Phase 2 with slots for tumors with known ARID1A mutations in Lymphoma, Mesothelioma, Urothelial and Endometrial. 

Study Design:  Drug is given orally daily.

GSK2857916 (DREAMM5)  (GlaxoSmithKline Research) 

Description:  As Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5

Target Patient Population:  Multiple Myeloma

Study Design:  Study Drug is administered IV every 3 weeks.  Combination arms with Belantamab + other anti-myeloma agents